Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours (Q43673455)

25 November 2017

title

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

Moodley D

1 reference

25 November 2017

Pillay K

1 reference

25 November 2017

Naidoo K

1 reference

25 November 2017

Moodley J

1 reference

25 November 2017

Johnson MA

1 reference

25 November 2017

Moore KH

1 reference

25 November 2017

Mudd PN Jr

1 reference

25 November 2017

Pakes GE

1 reference

25 November 2017

publication date

1 July 2001

1 reference

The Journal of Clinical Pharmacology

25 November 2017

published in

1 reference

25 November 2017

1 reference

25 November 2017

1 reference

25 November 2017

page(s)

732-741

1 reference

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Tran

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus–1 transmission in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African Developing country setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. Ghent International Working Group on Mother-to-Child Transmission of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Clinical pharmacokinetics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Placental transfer of drugs administered to the mother

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Pharmacokinetics of anti-infective agents in paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Transfer of zidovudine (AZT) by human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

The maternal-fetal transfer of lamivudine in the ex vivo human placenta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010636

10.1177/00912700122010636

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference